

Appl. No. : 09/781,023  
Filed : February 9, 2001

74. (New) The method of Claim 73, wherein the APC's are from the mammal being treated.

75. (New) The method of Claim 20, further comprising:  
co-culturing antigen-presenting cells (APCs) with the urine isolate; and  
reinfusing an effective amount of the APCs or exosomes from the APCs into the  
mammal with cancer.

76. (New) The method of Claim 75, wherein said APCs are dendritic cells.

77. (New) The method of Claim 20, wherein the urine isolate is administered within  
exosomes.

78. (New) The method of Claim 77, wherein said exosomes are obtained from APC's  
which are co-cultured with the urine isolate.

79. (New) The method of Claim 73, wherein the APC's are from the mammal being  
treated.

#### REMARKS

Applicants acknowledge receipt of the Restriction Requirement mailed October 30, 2001 (Paper No. 5). In response to the Restriction Requirement Applicants have elected to prosecute Group I, Claims 1-34, drawn to a method of treating cancer and cachexia with a urine isolate. Claims 70-78 have been added to more thoroughly claim the invention. Support for added claims 70-78 can be found in the claims as filed (see, in particular Claim 35) as well as the Examples, such as Example 14. Although some of these claims recite elements of the non-elected invention, they all are dependant from one of the elected claims. As such, the claims read on the elected invention and examination thereof is respectfully requested. No new matter has been added herewith.

The changes made to the Specification by the current amendment, including **[deletions]** and additions, are shown on the attached sheet entitled **VERSION WITH MARKINGS TO SHOW CHANGES MADE**, which follows the signature page of this Amendment.

Appl. No. : 09/781,023  
Filed : February 9, 2001

**Conclusion**

As a result of the amendments made herein, Claims 1-35 and 71-78 are presented for Examination. Should any clarification be needed, the Examiner is respectfully invited to contact the undersigned attorney at the telephone number appearing below.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 5 Dec. 2001

By: Daniel Altman  
Daniel E. Altman  
Registration No. 34,115  
Attorney of Record  
620 Newport Center Drive  
Sixteenth Floor  
Newport Beach, CA 92660

H:\DOCS\VAHV\AH-5215.DOC  
120301

Appl. No. : 09/781,023  
Filed : February 9, 2001

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**IN THE SPECIFICATION**

On page 15, lines 30 through page 16, line 4, please amend the third complete paragraph (EXAMPLE 12), as follows:

--A 37 year old Caucasian female with infiltrating ductal adenocarcinoma of the left breast with localized spread to the axillary lymph nodes was treated with dendritic cells and exosomes prepared by harvesting the media from the growing dendritic cells pulsed with autologous HIU (isolated as described in Example 1). After 2 weekly injections **[[INJECTED WHERE??]]** of dendritic cells and exosomes, the primary tumor mass and the axillary adenopathy decreased by approximately 30%.--.

On page 16, line 8-13, in the first complete paragraph (EXAMPLE 13), please amend the paragraph as follows:

--A 48 year old Caucasian female with ductal carcinoma of the left breast with metastases to the bones, and lungs was treated with dendritic cells and exosomes prepared as described— dendritic cells were pulsed with autologous HIU (prepared as in Example 1). After 4 weekly injections of dendritic cells and exosomes**[[Injected where?]]**, 70% of the bone metastases had resolved and the lung metastases were reduced in size by approximately 60%.--.